Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DML53ZJ)

Drug Name
Mirtazapine Drug Info
Synonyms
Avanza; Axit; Azamianserin; Mepirzapin; Mepirzepine; Mirtabene; Mirtaz; Mirtazapina; Mirtazapinum; Mirtazepine; Mirtazipine; Mirtazon; Norset; Promyrtil; Remergil; Remergon; Remeron; Rexer; Zispin; Celltech brand of mirtazapine; Mundogen brand of mirtazapine; Organon brand of mirtazapine; Remeron SolTab; ORG 3770; Afloyan (TN); Alphamirt (TN); Alphazagen (TN); Amirel (TN); Arintapin (TN); Arintapina (TN); Avanza (TN); Axit (TN); Bexzis (TN); Calixta (TN); Ciblex (TN); Combar (TN); Comenter (TN); Divaril (TN); Esprital (TN); Finmirtaza (TN); Finpharma (TN); Finscope (TN); Genamirt (TN); Hexazipin (TN); Loxozapin (TN); ME-2040; Medizapin (TN); Miralix (TN); Mirap (TN); Mirazep (TN); Miro (TN); Miron (TN); Mirta (TN); Mirtabene (TN); Mirtachem (TN); Mirtacur (TN); Mirtadepi (TN); Mirtagamma (TN); Mirtal (TN); Mirtalich (TN); Mirtalphagen (TN); Mirtamed (TN); Mirtamerck (TN); Mirtapax (TN); Mirtapharm (TN); Mirtapin(TN); Mirtaratio (TN); Mirtaril (TN); Mirtaron (TN); Mirtascope (TN); Mirtasole (TN); Mirtastad (TN); Mirtastada (TN); Mirtatifi (TN); Mirtatsapiini (TN); Mirtawin (TN); Mirtaz (TN); Mirtazapin (TN);Mirtazapina (TN); Mirtazapina [INN-Spanish]; Mirtazapinum [INN-Latin]; Mirtazelon (TN); Mirtazen (TN); Mirtazep (TN); Mirtazepin (TN); Mirtazon (TN); Mirtazza (TN); Mirtel (TN); Mirtoral (TN); Mirzagen (TN); Mirzalux (TN); Mirzaten (TN); Mitrazen (TN); Mizapin (TN); Mizapin Sol (TN); Norset (TN); Noxibel (TN); Pharmasole (TN); Pharmazepine (TN); Promyrtil (TN); Remergil (TN); Remergon (TN); Remeron (TN); Remeron SolTab (TN); Remirta (TN); Rexer (TN); SolTab (TN); Tarzapine (TN); Tazamel (TN); Tazapin (TN); Tazascope (TN); Tirzamed (TN); Valdren (TN); Vastat (TN); Zapex (TN); Zicomber (TN); Zismirt (TN); Zispin (TN); Zispin SolTab (TN); Zuleptan (TN); Mirtazapine [USAN:BAN:INN]; Mirtazapine [USAN:INN:BAN]; Mirzaten Q-Tab (TN); Zistap. (TN); Mirtazapine (JAN/USAN/INN); (1)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino(2,1-a)pyrido(2,3-c)(2)benzazepine; (N-methyl-11C)mirtazapine; 1,2,3,4,10,14b-Hexahydro-2-methylpyrazino(2,1-a)pyrido(2,3-c)benzazepine; 1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine; 2-Methyl-1,2,3,4,10,14b-hexahydropyrazino[2,1-a]pyrido[2,3-c][2]benzazepine; 5-methyl-2,5,19-triazatetracyclo[13.4.0.0^{2,7}.0^{8,13}]nonadeca-1(15),8(13),9,11,16,18-hexaene; 6-Azamianserin
Indication
Disease Entry ICD 11 Status REF
Depression 6A70-6A7Z Approved [1]
Therapeutic Class
Antidepressants
Cross-matching ID
PubChem CID
4205
ChEBI ID
CHEBI:6950
CAS Number
CAS 85650-52-8
TTD Drug ID
DML53ZJ
INTEDE Drug ID
DR1098
ACDINA Drug ID
D00439

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DME
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting 5-HT 2C receptor (HTR2C)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metergolin DMJFP6G Hyperprolactinaemia 5A60.1 Approved [9]
Lorcaserin DMG6OYJ Obesity 5B81 Approved [10]
Tramadol DMRQD04 Osteoarthritis FA00-FA05 Approved [11]
Nefazodone DM4ZS8M Major depressive disorder 6A70.3 Approved [12]
Methysergide DM1EF73 Migraine 8A80 Approved [13]
Eltoprazine DMW6C81 Attention deficit hyperactivity disorder 6A05.Z Phase 3 [14]
M100907 DM7ZFBA Sleep-wake disorder 7A00-7B2Z Phase 3 [15]
SR46349B DM1ODMR Primary insomnia 7A00 Phase 3 [16]
Vabicaserin DM9GZW6 Psychotic disorder 6A20-6A25 Phase 2 [17]
Nuplazid DMOJA5G Alzheimer disease 8A20 Phase 2 [18]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 3A4 (CYP3A4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [19]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [20]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [21]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [22]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [23]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [24]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [25]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [26]
Prasterone DM67VKL Chronic obstructive pulmonary disease CA22 Approved [20]
Verapamil DMA7PEW Angina pectoris BA40 Approved [27]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 1A2 (CYP1A2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Fluorouracil DMUM7HZ Adenocarcinoma 2D40 Approved [28]
Dinoprostone DMTYOPD Medical abortion JA00.1Z Approved [29]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [30]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [31]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [32]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [33]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [25]
Oxaliplatin DMQNWRD Adenocarcinoma 2D40 Approved [34]
Verapamil DMA7PEW Angina pectoris BA40 Approved [35]
Diclofenac DMPIHLS Chronic renal failure GB61.Z Approved [36]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 2D6 (CYP2D6)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [37]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [38]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [39]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [23]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [27]
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [40]
Propofol DMB4OLE Anaesthesia 9A78.6 Approved [41]
Dopamine DMPGUCF Acromegaly 5A60.0 Approved [42]
Nicotine DMWX5CO Lung cancer 2C25.0 Approved [43]
Propranolol DM79NTF Angina pectoris BA40 Approved [44]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 2C8 (CYP2C8)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Fluorouracil DMUM7HZ Adenocarcinoma 2D40 Approved [28]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [45]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [45]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [4]
Verapamil DMA7PEW Angina pectoris BA40 Approved [46]
Diclofenac DMPIHLS Chronic renal failure GB61.Z Approved [47]
Sorafenib DMS8IFC Adenocarcinoma 2D40 Approved [48]
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [45]
Mycophenolate mofetil DMPQAGE Hepatosplenic T-cell lymphoma Approved [49]
Propofol DMB4OLE Anaesthesia 9A78.6 Approved [50]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 2C9 (CYP2C9)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Progesterone DMUY35B Amenorrhea GA20.0 Approved [51]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [52]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [53]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [4]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [54]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [4]
Verapamil DMA7PEW Angina pectoris BA40 Approved [55]
Diclofenac DMPIHLS Chronic renal failure GB61.Z Approved [56]
Estrone DM5T6US Acne vulgaris ED80 Approved [57]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [58]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Stearoyl-CoA desaturase (SCD)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Clavulanate DM2FGRT Bacteremia 1A73 Approved [59]
Citalopram DM2G9AE Acute coronary syndrome BA41 Approved [6]
Imipramine DM2NUH3 Depression 6A70-6A7Z Approved [6]
Methotrexate DM2TEOL Anterior urethra cancer Approved [60]
Quercetin DM3NC4M Obesity 5B81 Approved [61]
Rofecoxib DM3P5DA Osteoarthritis FA00-FA05 Approved [62]
Fluoxetine DM3PD2C Bipolar depression Approved [6]
Fructose DM43AN2 Vomiting MD90 Approved [63]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [64]
Bupropion DM5PCS7 Depression 6A70-6A7Z Approved [6]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Prolactin (PRL)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Verapamil DMA7PEW Angina pectoris BA40 Approved [65]
Ranitidine DM0GUSX Gastric ulcer DA60 Approved [66]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [67]
Citalopram DM2G9AE Acute coronary syndrome BA41 Approved [68]
Methotrexate DM2TEOL Anterior urethra cancer Approved [60]
Thioridazine DM35M8J Schizophrenia 6A20 Approved [69]
Naloxone DM3FXMA Narcotic depression 6A7Z Approved [70]
Aripiprazole DM3NUMH Bipolar I disorder Approved [71]
Fluoxetine DM3PD2C Bipolar depression Approved [72]
Penicillamine DM40EF6 Cystinuria 5C60.2 Approved [73]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Solute carrier family 2, facilitated glucose transporter member 4 (SLC2A4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dexamethasone DMMWZET Acute adrenal insufficiency Approved [74]
Fructose DM43AN2 Vomiting MD90 Approved [63]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [75]
Glucosamine DM4ZLFD Osteoarthritis FA00-FA05 Approved [76]
Testosterone DM7HUNW Hot flushes GA30 Approved [77]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [77]
Haloperidol DM96SE0 Delirium Approved [8]
Leflunomide DMR8ONJ Arthritis FA20 Approved [78]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [79]
Rosiglitazone DMILWZR Chronic kidney disease GB61 Approved [80]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Solute carrier family 2, facilitated glucose transporter member 5 (SLC2A5)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Fructose DM43AN2 Vomiting MD90 Approved [81]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [64]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [82]
Hydroquinone DM6AVR4 Melasma ED60.1 Approved [83]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [84]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [85]
Demecolcine DMCZQGK Solid tumour/cancer 2A00-2F9Z Approved [86]
Pioglitazone DMKJ485 Amyotrophic lateral sclerosis 8B60.0 Approved [87]
Methamphetamine DMPM4SK Anxiety Approved [88]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [89]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Hydroxymethylglutaryl-CoA synthase, cytoplasmic (HMGCS1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [90]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [91]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [92]
Citalopram DM2G9AE Acute coronary syndrome BA41 Approved [6]
Imipramine DM2NUH3 Depression 6A70-6A7Z Approved [6]
Quercetin DM3NC4M Obesity 5B81 Approved [93]
Fluoxetine DM3PD2C Bipolar depression Approved [6]
obeticholic acid DM3Q1SM Primary biliary cholangitis DB96.1 Approved [94]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [95]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [64]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
5-HT 2C receptor (HTR2C) TTWJBZ5 5HT2C_HUMAN Antagonist [2]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [3]
Cytochrome P450 2D6 (CYP2D6) Main DME DECB0K3 CP2D6_HUMAN Substrate [3]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Substrate [4]
Cytochrome P450 1A2 (CYP1A2) Main DME DEJGDUW CP1A2_HUMAN Substrate [5]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Substrate [4]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Hydroxymethylglutaryl-CoA synthase, cytoplasmic (HMGCS1) OTCO26FV HMCS1_HUMAN Gene/Protein Processing [6]
Prolactin (PRL) OTWFQGX7 PRL_HUMAN Gene/Protein Processing [7]
Solute carrier family 2, facilitated glucose transporter member 4 (SLC2A4) OTJZG0LD GLUT4_HUMAN Gene/Protein Processing [8]
Solute carrier family 2, facilitated glucose transporter member 5 (SLC2A5) OTZNYEKF GTR5_HUMAN Gene/Protein Processing [8]
Stearoyl-CoA desaturase (SCD) OTB1073G SCD_HUMAN Gene/Protein Processing [6]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7241).
2 Inverse agonist and neutral antagonist actions of antidepressants at recombinant and native 5-hydroxytryptamine2C receptors: differential modulatio... Mol Pharmacol. 2008 Mar;73(3):748-57.
3 A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev. 2001 Fall;7(3):249-64.
4 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
5 Impact of the CYP2D6 ultrarapid metabolizer genotype on mirtazapine pharmacokinetics and adverse events in healthy volunteers. J Clin Psychopharmacol. 2004 Dec;24(6):647-52.
6 Antidepressant drugs activate SREBP and up-regulate cholesterol and fatty acid biosynthesis in human glial cells. Neurosci Lett. 2006 Mar 13;395(3):185-90. doi: 10.1016/j.neulet.2005.10.096. Epub 2005 Dec 1.
7 [Gynecomastia-galactorrhea during treatment with mirtazapine]. Presse Med. 2004 Apr 10;33(7):458. doi: 10.1016/s0755-4982(04)98631-9.
8 Effects of different antipsychotics and the antidepressant mirtazapine on glucose transporter mRNA levels in human blood cells. J Psychiatr Res. 2006 Jun;40(4):374-9. doi: 10.1016/j.jpsychires.2005.04.016. Epub 2005 Jul 5.
9 Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23.
10 Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50.
11 The inhibitory effects of tramadol on 5-hydroxytryptamine type 2C receptors expressed in Xenopus oocytes. Anesth Analg. 2004 May;98(5):1401-6, table of contents.
12 Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies. Therapie. 2005 Sep-Oct;60(5):441-60.
13 Spinal serotonin receptor activation modulates the exercise ventilatory response with increased dead space in goats. Respir Physiol Neurobiol. 2008 May 31;161(3):230-8.
14 Clinical pipeline report, company report or official report of Jazz Pharmaceuticals.
15 Non-basic ligands for aminergic GPCRs: the discovery and development diaryl sulfones as selective, orally bioavailable 5-HT2A receptor antagonists ... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3708-12.
16 SR46349-B, a 5-HT(2A/2C) receptor antagonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Neuropsychopharmacology. 2002 Sep;27(3):430-41.
17 Prediction of Efficacy of Vabicaserin, a 5-HT2C Agonist, for the Treatment of Schizophrenia Using a Quantitative Systems Pharmacology Model.CPT Pharmacometrics Syst Pharmacol.2014 Apr 23;3:e111.
18 The neuropharmacology of sleep paralysis hallucinations: serotonin 2A activation and a novel therapeutic drug. Psychopharmacology (Berl). 2018 Nov;235(11):3083-3091.
19 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
20 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
21 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
22 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
23 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
24 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
25 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
26 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
27 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
28 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
29 Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
30 Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
31 Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
32 PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
33 The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
34 The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
35 Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
36 Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
37 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
38 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
39 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
40 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
41 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
42 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
43 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
44 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
45 Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
46 Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics. 2003 Sep;13(9):565-75.
47 Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants. Biochemistry. 2004 Dec 14;43(49):15379-92.
48 Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8.
49 PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
50 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
51 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
52 Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
53 Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
54 Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
55 Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
56 New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
57 A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
58 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
59 Molecular mechanisms of hepatotoxic cholestasis by clavulanic acid: Role of NRF2 and FXR pathways. Food Chem Toxicol. 2021 Dec;158:112664. doi: 10.1016/j.fct.2021.112664. Epub 2021 Nov 9.
60 The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
61 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
62 Rofecoxib modulates multiple gene expression pathways in a clinical model of acute inflammatory pain. Pain. 2007 Mar;128(1-2):136-47.
63 Effects of four-week high-fructose diet on gene expression in skeletal muscle of healthy men. Diabetes Metab. 2008 Feb;34(1):82-5. doi: 10.1016/j.diabet.2007.08.004. Epub 2007 Dec 11.
64 Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharmacol. 2004 Dec 1;68(11):2177-86.
65 Verapamil-induced hyperprolactinemia complicated by a pituitary incidentaloma. Ann Pharmacother. 1995 Oct;29(10):999-1001. doi: 10.1177/106002809502901009.
66 [Impotence and gynecomastia secondary to hyperprolactinemia induced by ranitidine]. Therapie. 1994 Jul-Aug;49(4):361-2.
67 Differential effects of estrogen receptor antagonists on pituitary lactotroph proliferation and prolactin release. Mol Cell Endocrinol. 2005 Jul 15;239(1-2):27-36. doi: 10.1016/j.mce.2005.04.008.
68 Cholinergic modulation of the cerebral metabolic response to citalopram in Alzheimer's disease. Brain. 2009 Feb;132(Pt 2):392-401. doi: 10.1093/brain/awn326. Epub 2009 Jan 19.
69 The effect of thioridazine on prolactinoma growth in a schizophrenic man: case report. Gen Hosp Psychiatry. 1985 Oct;7(4):364-6. doi: 10.1016/0163-8343(85)90053-2.
70 Influence of naloxone on muscle sympathetic nerve activity, systemic and calf haemodynamics and ambulatory blood pressure after exercise in mild essential hypertension. J Hypertens. 1995 Apr;13(4):447-61.
71 The efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trials. J Affect Disord. 2009 May;115(1-2):18-26. doi: 10.1016/j.jad.2008.12.017. Epub 2009 Feb 23.
72 Serum prolactin levels among outpatients with major depressive disorder during the acute phase of treatment with fluoxetine. J Clin Psychiatry. 2006 Jun;67(6):952-7. doi: 10.4088/jcp.v67n0612.
73 Massive breast enlargement in a patient receiving D-penicillamine for systemic sclerosis. J Rheumatol. 1985 Oct;12(5):990-1.
74 Anti-diabetic effect of oligosaccharides from seaweed Sargassum confusum via JNK-IRS1/PI3K signalling pathways and regulation of gut microbiota. Food Chem Toxicol. 2019 Sep;131:110562. doi: 10.1016/j.fct.2019.110562. Epub 2019 Jun 7.
75 Adipocyte differentiation, mitochondrial gene expression and fat distribution: differences between zidovudine and tenofovir after 6 months. Antivir Ther. 2009;14(8):1089-100. doi: 10.3851/IMP1457.
76 Glucosamine-induced endoplasmic reticulum stress affects GLUT4 expression via activating transcription factor 6 in rat and human skeletal muscle cells. Diabetologia. 2010 May;53(5):955-65. doi: 10.1007/s00125-010-1676-1. Epub 2010 Feb 18.
77 Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
78 Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
79 Valproic acid promotes mitochondrial dysfunction in primary human hepatocytes in vitro; impact of C/EBP-controlled gene expression. Arch Toxicol. 2020 Oct;94(10):3463-3473. doi: 10.1007/s00204-020-02835-x. Epub 2020 Jul 4.
80 Enhanced insulin-stimulated glycogen synthesis in response to insulin, metformin or rosiglitazone is associated with increased mRNA expression of GLUT4 and peroxisomal proliferator activator receptor gamma co-activator 1. Diabetologia. 2005 Jun;48(6):1173-9. doi: 10.1007/s00125-005-1741-3. Epub 2005 Apr 30.
81 Fructose modulates GLUT5 mRNA stability in differentiated Caco-2 cells: role of cAMP-signalling pathway and PABP (polyadenylated-binding protein)-interacting protein (Paip) 2. Biochem J. 2003 Oct 1;375(Pt 1):167-74. doi: 10.1042/BJ20030661.
82 In vitro study of transporters involved in intestinal absorption of inorganic arsenic. Chem Res Toxicol. 2012 Feb 20;25(2):446-53. doi: 10.1021/tx200491f. Epub 2012 Jan 26.
83 Keratinocyte-derived IL-36gama plays a role in hydroquinone-induced chemical leukoderma through inhibition of melanogenesis in human epidermal melanocytes. Arch Toxicol. 2019 Aug;93(8):2307-2320.
84 Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005 Nov;19(11):2685-95.
85 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
86 Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.
87 Peroxisome proliferator activated receptor gamma (PPAR-gama) ligand pioglitazone regulated gene networks in term human primary trophoblast cells. Reprod Toxicol. 2018 Oct;81:99-107.
88 Microglial and astrocytic changes in the striatum of methamphetamine abusers. Leg Med (Tokyo). 2010 Mar;12(2):57-62. doi: 10.1016/j.legalmed.2009.11.001. Epub 2010 Jan 27.
89 Low doses of cisplatin induce gene alterations, cell cycle arrest, and apoptosis in human promyelocytic leukemia cells. Biomark Insights. 2016 Aug 24;11:113-21.
90 Cannabidiol Displays Proteomic Similarities to Antipsychotics in Cuprizone-Exposed Human Oligodendrocytic Cell Line MO3.13. Front Mol Neurosci. 2021 May 28;14:673144. doi: 10.3389/fnmol.2021.673144. eCollection 2021.
91 DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
92 Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
93 Hypoxia-inducible factor-1 (HIF-1) pathway activation by quercetin in human lens epithelial cells. Exp Eye Res. 2009 Dec;89(6):995-1002. doi: 10.1016/j.exer.2009.08.011. Epub 2009 Sep 1.
94 Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
95 Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.